Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023

CROサービスの世界市場予測(~2023年):タイプ別(創薬研究、CMC、前臨床、臨床研究、ラボサービス)、治療領域別(腫瘍、CNS、心臓血管)、エンドユーザー別(医薬品と医療機器)

◆タイトル:Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023
◆商品コード:MAM-PH-4672
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年2月2日
◆ページ数:262
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、CROサービスの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、種類別分析、セグメント別分析、地域別分析、CROサービスの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・CROサービス市場:タイプ別
・グローバルCROサービス市場:治療領域別
・CROサービス市場:エンドユーザー別
・CROサービス市場:地域別
・競争状況
・企業プロファイル
・付録

“The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 7.6% between 2018 and 2023.”
The CRO services market is expected to reach USD 56.34 billion by 2023 from USD 39.13 billion in 2018, at a CAGR of 7.6%. Increased outsourcing of R&D activities and increasing number of clinical trials are some of the major factors driving the growth of this market. However, intense competition in the CRO services market is one of the major challenges for the players operating in the CRO services market.
“Laboratory services segment to witness the highest growth rate during the forecast period.”
Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing number of pipeline drugs and growing outsourcing of laboratory services by pharmaceutical and biopharmaceutical companies.
“Oncology segment to grow at the highest CAGR from 2018 to 2023.”
Oncology segment is expected to register the highest CAGR during the forecast period. The increasing number of clinical trials and rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.
“APAC to witness the highest growth rate during the forecast period.”
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.
Break of primary participants:
• By Company Type – Tier 1: 21%, Tier 2–26%, and Tier 3–53%
• By Designation – C Level: 32%, Director Level: 26%, and Others: 42%
• By Region – North America: 26%, Europe: 35%, Asia Pacific: 20%, Latin America: 11%, and the Middle East & Africa: 8%
Research Coverage:
The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.
The report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
 Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
 Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
 Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
 Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
2.1.2.1 Key data from primary sources 26
2.1.2.2 Key industry insights 27
2.2 MARKET SIZE ESTIMATION 28
2.2.1 BOTTOM-UP APPROACH 29
2.2.2 TOP-DOWN APPROACH 29
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 30
2.4 MARKET SHARE ESTIMATION 31
2.5 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 CRO SERVICES MARKET OVERVIEW 35
4.2 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE AND COUNTRY 36
4.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37
4.4 CRO SERVICES MARKET: GEOGRAPHIC MIX 38
4.5 CRO SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 Growing R&D expenditure 41
5.2.1.2 Increased outsourcing of R&D activities 42
5.2.1.3 Increasing number of clinical trials 43
5.2.2 OPPORTUNITIES 44
5.2.2.1 Growth in the biosimilars and biologics markets 44
5.2.2.2 Rising demand for specialized testing services 45
5.2.2.3 Emerging Asian markets 46
5.2.3 CHALLENGES 47
5.2.3.1 Intense competition in the cro services market 47
5.2.3.2 Shortage of skilled professionals 47
5.3 INDUSTRY TRENDS 48
5.3.1 GROWING CONSOLIDATION IN THE CRO INDUSTRY 48
5.3.2 INCREASING OUTSOURCING OF CLINICAL TRIALS TO EMERGING MARKETS 50
5.3.3 ADOPTION OF NEW TECHNOLOGIES 51
6 CRO SERVICES MARKET, BY TYPE 52
6.1 INTRODUCTION 53
6.2 CLINICAL RESEARCH SERVICES 54
6.2.1 PHASE I CLINICAL RESEARCH SERVICES 57
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 59
6.2.3 PHASE III CLINICAL RESEARCH SERVICES 60
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 62
6.3 EARLY-PHASE DEVELOPMENT SERVICES 63
6.3.1 DISCOVERY STUDIES 66
6.3.2 CHEMISTRY, MANUFACTURING, & CONTROL (CMC) 67
6.3.3 PRECLINICAL SERVICES 68
6.3.3.1 Pharmacokinetics/pharmacodynamics (PK/PD) 70
6.3.3.2 Toxicology testing services 71
6.3.3.3 Other preclinical services 72
6.4 LABORATORY SERVICES 73
6.4.1 BIOANALYTICAL TESTING SERVICES 75
6.4.2 ANALYTICAL TESTING SERVICES 76
6.4.2.1 Physical characterization 77
6.4.2.2 Raw material testing 78
6.4.2.3 Batch-release testing 79
6.4.2.4 Stability testing 80
6.4.2.5 Other analytical testing services 82
6.5 CONSULTING SERVICES 82
7 GLOBAL CRO SERVICES MARKET, BY THERAPEUTIC AREA 85
7.1 INTRODUCTION 86
7.2 ONCOLOGY 87
7.3 INFECTIOUS DISEASES 90
7.4 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 92
7.5 IMMUNOLOGICAL DISORDERS 94
7.6 CARDIOVASCULAR DISEASES 96
7.7 RESPIRATORY DISORDERS 99
7.8 DIABETES 100
7.9 OTHER THERAPEUTIC AREAS 102
8 CRO SERVICES MARKET, BY END USER 104
8.1 INTRODUCTION 105
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 106
8.3 MEDICAL DEVICE COMPANIES 108
8.4 ACADEMIC INSTITUTES 109
9 CRO SERVICES MARKET, BY REGION 111
9.1 INTRODUCTION 112
9.2 NORTH AMERICA 113
9.2.1 US 118
9.2.2 CANADA 123
9.3 EUROPE 127
9.3.1 GERMANY 133
9.3.2 UK 137
9.3.3 FRANCE 141
9.3.4 ITALY 145
9.3.5 SPAIN 149
9.3.6 REST OF EUROPE 153
9.4 ASIA PACIFIC 157
9.4.1 CHINA 163
9.4.2 JAPAN 168
9.4.3 INDIA 171
9.4.4 REST OF ASIA PACIFIC 176
9.5 LATIN AMERICA 181
9.6 MIDDLE EAST & AFRICA 185
10 COMPETITIVE LANDSCAPE 190
10.1 OVERVIEW 190
10.2 MARKET SHARE ANALYSIS 191
10.3 COMPETITIVE SCENARIO 195
10.3.1 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS (2014-2017) 195
10.3.2 SERVICE LAUNCHES (2014-2017) 195
10.3.3 EXPANSIONS (2014-2017) 196
10.3.4 ACQUISITIONS (2014-2017) 196

11 COMPANY PROFILES 197
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
11.1 IQVIA 197
11.2 LABCORP 202
11.3 PAREXEL 207
11.4 PRA HEALTH SCIENCES 212
11.5 PPD 216
11.6 ICON PLC 220
11.7 SYNEOS HEALTH 225
11.8 WUXI PHARMATECH 230
11.9 CHARLES RIVER 234
11.10 MEDPACE HOLDINGS 238
11.11 SGS 241
11.12 ENVIGO 246
11.13 MPI RESEARCH 247
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
12 APPENDIX 249
12.1 INSIGHTS OF INDUSTRY EXPERTS 249
12.2 DISCUSSION GUIDE 250
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 254
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 256
12.5 AVAILABLE CUSTOMIZATIONS 258
12.6 RELATED REPORTS 259
12.7 AUTHOR DETAILS 260

LIST OF TABLES

TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 22
TABLE 2 R&D EXPENDITURE & PERCENTAGE CHANGE, BY PHARMACEUTICAL COMPANY (2014–2016) 41
TABLE 3 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH 43
TABLE 4 LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN THE US, 2016 44
TABLE 5 CLINICAL STUDIES FOR BIOLOGIC & BIOSIMILAR MOLECULES (2017) 45
TABLE 6 GROWING BIOSIMILARS AND BIOLOGICS MARKETS TO PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES 46
TABLE 7 INTENSE COMPETITION IN THE CRO SERVICES MARKET IS A MAJOR CHALLENGE IN THE MARKET 47
TABLE 8 MAJOR MERGERS AND ACQUISITIONS IN CRO INDUSTRY (2013-2017) 49
TABLE 9 CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 53
TABLE 10 CRO SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 54
TABLE 11 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES,
BY LOCATION, 2017 55
TABLE 12 KEY CLINICAL RESEARCH SERVICES OFFERED BY PROMINENT PLAYERS 55
TABLE 13 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 56
TABLE 14 CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 57
TABLE 15 COMPLETED PHASE II STUDIES FOR DIFFERENT THERAPEUTIC AREAS 58
TABLE 16 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 58
TABLE 17 COMPLETED PHASE II STUDIES FOR DIFFERENT THERAPEUTIC AREAS 59
TABLE 18 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 60
TABLE 19 COMPLETED PHASE III STUDIES FOR DIFFERENT THERAPEUTIC AREAS 61
TABLE 20 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 61
TABLE 21 COMPLETED PHASE IV STUDIES FOR DIFFERENT THERAPEUTIC AREAS 62
TABLE 22 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 63
TABLE 23 KEY EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY PROMINENT PLAYERS 64
TABLE 24 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 65
TABLE 25 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 65
TABLE 26 DISCOVERY STUDIES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 67
TABLE 27 CHEMISTRY, MANUFACTURING, & CONTROL MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 68
TABLE 28 PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 69
TABLE 29 PRECLINICAL SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 69
TABLE 30 PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 70
TABLE 31 TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 71
TABLE 32 OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 72
TABLE 33 LABORATORY SERVICES: KEY SERVICES OFFERED BY PROMINENT PLAYERS 73
TABLE 34 LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 74
TABLE 35 LABORATORY SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 74
TABLE 36 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 75
TABLE 37 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 76
TABLE 38 ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 77
TABLE 39 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 78
TABLE 40 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 79
TABLE 41 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 80
TABLE 42 STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 81
TABLE 43 OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 82
TABLE 44 CONSULTING SERVICES: KEY SERVICES OFFERED BY PROMINENT PLAYERS 83
TABLE 45 CONSULTING SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 84
TABLE 46 GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS, 2017 86
TABLE 47 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 87
TABLE 48 CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 90
TABLE 49 LIST OF PIPELINE DRUGS FOR INFECTIOUS DISEASES (2016) 91
TABLE 50 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2016–2023 (USD MILLION) 92
TABLE 51 LIST OF PIPELINE DRUGS FOR CNS DISORDERS (2016) 93
TABLE 52 CRO SERVICES MARKET FOR CNS DISORDERS, BY COUNTRY,
2016–2023 (USD MILLION) 94
TABLE 53 PREVALENCE OF PID, BY REGION, 2013 VS. 2015 95
TABLE 54 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2016) 95
TABLE 55 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY,
2016–2023 (USD MILLION) 96
TABLE 56 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2016) 97
TABLE 57 CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2016–2023 (USD MILLION) 98
TABLE 58 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2016) 99
TABLE 59 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY,
2016–2023 (USD MILLION) 100
TABLE 60 LIST OF PIPELINE DRUGS FOR DIABETES (2016) 101
TABLE 61 CRO SERVICES MARKET FOR DIABETES, BY COUNTRY, 2016–2023 (USD MILLION) 102
TABLE 62 LIST OF PIPELINE DRUGS FOR OTHER THERAPEUTIC AREAS (2016) 103
TABLE 63 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2016–2023 (USD MILLION) 103
TABLE 64 CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 105
TABLE 65 NUMBER OF BIOPHARMACEUTICAL DRUGS IN DEVELOPMENT ACROSS
THE GLOBE, 2016 107
TABLE 66 CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION) 107
TABLE 67 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY,
2016–2023 (USD MILLION) 109
TABLE 68 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,
2016–2023 (USD MILLION) 110
TABLE 69 CRO SERVICES MARKET, BY REGION, 2016–2023 (USD MILLION) 113
TABLE 70 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 115
TABLE 71 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 115
TABLE 72 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 115
TABLE 73 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 116
TABLE 74 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 116
TABLE 75 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 117
TABLE 76 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 117
TABLE 77 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 118
TABLE 78 NORTH AMERICA: CRO SERVICES MARKET, BY END USER,
2016–2023 (USD MILLION) 118
TABLE 79 TOTAL NUMBER OF CLINICAL TRIALS IN THE US (2017) 119
TABLE 80 US: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 81 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 120
TABLE 82 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 121
TABLE 83 US: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 121
TABLE 84 US: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 121
TABLE 85 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 122
TABLE 86 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 122
TABLE 87 US: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 123
TABLE 88 CANADA: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 124
TABLE 89 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 124
TABLE 90 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 124
TABLE 91 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 125
TABLE 92 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 93 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 126
TABLE 94 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 126
TABLE 95 CANADA: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 127
TABLE 96 EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2012 VS. 2014 128
TABLE 97 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 130
TABLE 98 EUROPE: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 99 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 131
TABLE 100 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 131
TABLE 101 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 131
TABLE 102 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 132
TABLE 103 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 132
TABLE 104 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 133
TABLE 105 EUROPE: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 133
TABLE 106 GERMANY: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 134
TABLE 107 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 134
TABLE 108 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 109 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 135
TABLE 110 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 111 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 136
TABLE 112 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 136
TABLE 113 GERMANY: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 137
TABLE 114 UK: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 115 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 138
TABLE 116 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 117 UK: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 139
TABLE 118 UK: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 139
TABLE 119 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 140
TABLE 120 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 140
TABLE 121 UK: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 141
TABLE 122 FRANCE: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 123 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 142
TABLE 124 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 143
TABLE 125 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 143
TABLE 126 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 143
TABLE 127 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 144
TABLE 128 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 144
TABLE 129 FRANCE: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 145
TABLE 130 CLINICAL TRIALS IN ITALY (2013 VS. 2014) 145
TABLE 131 ITALY: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 132 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 146
TABLE 133 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 147
TABLE 134 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 147
TABLE 135 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 147
TABLE 136 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 148
TABLE 137 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 148
TABLE 138 ITALY: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 149
TABLE 139 SPAIN: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 140 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 150
TABLE 141 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 142 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 151
TABLE 143 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 151
TABLE 144 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 152
TABLE 145 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 152
TABLE 146 SPAIN: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 153
TABLE 147 PHARMACEUTICAL R&D EXPENDITURE & PRODUCTION IN ROE COUNTRIES
(2012 VS. 2014) 154
TABLE 148 ROE: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 154
TABLE 149 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 154
TABLE 150 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 151 ROE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 155
TABLE 152 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 153 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 156
TABLE 154 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 156
TABLE 155 ROE: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 157
TABLE 156 TOTAL NUMBER OF CLINICAL TRIALS IN ASIA PACIFIC,
BY THERAPEUTIC AREA, 2017 157
TABLE 157 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 159
TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 159
TABLE 159 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 160
TABLE 160 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 160
TABLE 161 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 161
TABLE 162 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 161
TABLE 163 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 162
TABLE 164 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 162
TABLE 165 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 163
TABLE 166 TOTAL NUMBER OF CLINICAL TRIALS IN CHINA, BY THERAPEUTIC AREA, 2017 164
TABLE 167 CHINA: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 164
TABLE 168 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 165
TABLE 169 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 165
TABLE 170 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 166
TABLE 171 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 166
TABLE 172 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 166
TABLE 173 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 167
TABLE 174 CHINA: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 167
TABLE 175 JAPAN: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 168
TABLE 176 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 177 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 169
TABLE 178 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 179 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 180 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 170
TABLE 181 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 171
TABLE 182 JAPAN: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 171
TABLE 183 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 172
TABLE 184 INCREASE IN R&D EXPENDITURE OF TOP 5 INDIAN PHARMACEUTICAL COMPANIES (2010 VS. 2017) 172
TABLE 185 INDIA: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 173
TABLE 186 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 173
TABLE 187 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 173
TABLE 188 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 174
TABLE 189 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 174
TABLE 190 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 175
TABLE 191 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 175
TABLE 192 INDIA: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 176
TABLE 193 TOTAL NUMBER OF CLINICAL TRIALS IN AUSTRALIA, SINGAPORE, & MALAYSIA,
BY THERAPEUTIC AREA, 2017 177
TABLE 194 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 177
TABLE 195 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 177
TABLE 196 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 178
TABLE 197 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 178
TABLE 198 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 179
TABLE 199 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 179
TABLE 200 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 180
TABLE 201 ROAPAC: CRO SERVICES MARKET, BY END USER, 2016–2023 (USD MILLION) 180
TABLE 202 TOTAL NUMBER OF CLINICAL TRIALS IN LATIN AMERICA,
BY THERAPEUTIC AREA, 2017 181
TABLE 203 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 182
TABLE 204 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 182
TABLE 205 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 182
TABLE 206 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 183
TABLE 207 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 183
TABLE 208 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 184
TABLE 209 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 184
TABLE 210 LATIN AMERICA: CRO SERVICES MARKET, BY END USER,
2016–2023 (USD MILLION) 185
TABLE 211 TOTAL NUMBER OF CLINICAL TRIALS IN THE MIDDLE EAST AND AFRICA,
BY THERAPEUTIC AREA, 2017 186
TABLE 212 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 186
TABLE 213 MIDDLE EAST AND AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY TYPE, 2016–2023 (USD MILLION) 186
TABLE 214 MIDDLE EAST AND AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 187
TABLE 215 MIDDLE EAST AND AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 187
TABLE 216 MIDDLE EAST AND AFRICA: LABORATORY SERVICES MARKET, BY TYPE,
2016–2023 (USD MILLION) 188
TABLE 217 MIDDLE EAST AND AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 188
TABLE 218 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 189
TABLE 219 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY END USER,
2016–2023 (USD MILLION) 189
TABLE 220 GROWTH STRATEGY MATRIX (2014–2017) 191


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 24
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 28
FIGURE 3 DATA TRIANGULATION METHODOLOGY 30
FIGURE 4 CRO SERVICES MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION) 32
FIGURE 5 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018 VS. 2023 (USD BILLION) 33
FIGURE 6 CRO SERVICES MARKET, BY END USER, 2018 VS. 2023 (USD BILLION) 33
FIGURE 7 GEOGRAPHIC SNAPSHOT: CRO SERVICES MARKET 34
FIGURE 8 GROWING R&D EXPENDITURE AND INCREASE IN NUMBER OF CLINICAL
TRIALS TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 35
FIGURE 9 PHASE III SEGMENT WILL CONTINUE TO DOMINATE APAC CLINICAL RESEARCH SERVICES MARKET DURING THE FORECAST PERIOD 36
FIGURE 10 THE US DOMINATED THE CRO SERVICES MARKET IN 2017 37
FIGURE 11 NORTH AMERICA TO DOMINATE THE CRO SERVICES MARKET DURING THE FORECAST PERIOD 38
FIGURE 12 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 39
FIGURE 13 CONTRACT RESEARCH ORGANIZATION (CRO) SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 40
FIGURE 14 NUMBER OF NEW CHEMICAL OR BIOLOGICAL ENTITIES (1997–2016) 42
FIGURE 15 TOTAL NUMBER OF REGISTERED STUDIES (2005–2017) 43
FIGURE 16 TOTAL NUMBER OF NEW MOLECULAR ENTITY (NME) AND NEW BIOLOGIC LICENSE APPLICATION (BLA) FILINGS AND APPROVALS IN THE US, 2006–2015 44
FIGURE 17 KEY TRENDS IN THE CRO SERVICES MARKET 48
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL CRO SERVICES MARKET BY 2023 53
FIGURE 19 COMPARATIVE ANALYSIS OF CLINICAL TRIALS OVER THE YEARS (2010–2016) 55
FIGURE 20 BIOPHARMACEUTICAL DRUGS UNDER DEVELOPMENT,
BY THERAPEUTIC AREA, 2016 64
FIGURE 21 PHASES OF DRUG DISCOVERY STUDIES 66
FIGURE 22 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL CRO SERVICES MARKET BY 2023 86
FIGURE 23 WORLDWIDE CANCER INCIDENCE AND MORTALITY (2012–2025) 88
FIGURE 24 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY (2017) 89
FIGURE 25 DIABETES PREVALENCE, BY COUNTRY, 2015 (MILLION INDIVIDUALS) 101
FIGURE 26 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO DOMINATE THE CRO SERVICES MARKET DURING THE FORECAST PERIOD 105
FIGURE 27 R&D SPENDING OF PHRMA MEMBER COMPANIES, 1980–2015 106
FIGURE 28 CLINICAL STUDIES FOR MEDICAL DEVICES (2017) 108
FIGURE 29 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 112
FIGURE 30 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2017) 113
FIGURE 31 NORTH AMERICA: MARKET SNAPSHOT 114
FIGURE 32 PHARMACEUTICAL R&D EXPENDITURE IN THE US (1990–2014) 119
FIGURE 33 EUROPE: MARKET SNAPSHOT 129
FIGURE 34 ASIA PACIFIC: MARKET SNAPSHOT 158
FIGURE 35 KEY DEVELOPMENTS IN THE CRO SERVICES MARKET, 2014–2017 190
FIGURE 36 GLOBAL CRO SERVICES MARKET SHARE, BY KEY PLAYER, 2017 192
FIGURE 37 IQVIA: COMPANY SNAPSHOT 197
FIGURE 38 LABCORP: COMPANY SNAPSHOT 202
FIGURE 39 PAREXEL: COMPANY SNAPSHOT 207
FIGURE 40 PRA HEALTH SCIENCES: COMPANY SNAPSHOT 212
FIGURE 41 ICON PLC: COMPANY SNAPSHOT 220
FIGURE 42 INC RESEARCH HOLDINGS: COMPANY SNAPSHOT 225
FIGURE 43 WUXI PHARMATECH: COMPANY SNAPSHOT 230
FIGURE 44 CHARLES RIVER: COMPANY SNAPSHOT (2016) 234
FIGURE 45 MEDPACE HOLDINGS: COMPANY SNAPSHOT 238
FIGURE 46 SGS: COMPANY SNAPSHOT 241


★調査レポート[CROサービスの世界市場予測(~2023年):タイプ別(創薬研究、CMC、前臨床、臨床研究、ラボサービス)、治療領域別(腫瘍、CNS、心臓血管)、エンドユーザー別(医薬品と医療機器)] ( Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023 / MAM-PH-4672) 販売に関する免責事項
[CROサービスの世界市場予測(~2023年):タイプ別(創薬研究、CMC、前臨床、臨床研究、ラボサービス)、治療領域別(腫瘍、CNS、心臓血管)、エンドユーザー別(医薬品と医療機器)] ( Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023 / MAM-PH-4672) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆